Two responsibilities that must remain connected
The seat combines Risk Management Committee participation with CSR oversight. The connection is deliberate. A life-sciences organisation affects patients, customers, employees, communities and health systems through both its commercial operations and its social programmes. The director must ensure that risk decisions respect this consequence while preventing CSR from becoming brand activity detached from measurable need.
Enterprise risk agenda
The member will challenge the aggregation of quality, regulatory, supply, clinical or product, cyber/data, financial and reputation risks. The Board needs scenarios showing how a quality event, supply interruption or data failure travels across patients, regulators, revenue, liquidity and disclosure. Risk appetite should identify which standards are inviolable even under commercial or supply pressure.
Critical supply and manufacturing dependencies will be mapped beyond immediate vendors. Alternate qualification, inventory, cold or controlled conditions where relevant, transport, capacity and geopolitical exposure should be understood with realistic lead times. Contingency actions must be safe and regulatorily executable.
Technology and data oversight will cover sensitive information, access, third parties, validated systems, cyber detection and recovery. Restoration should establish accuracy and traceability, not merely availability. Material AI or analytical uses require ownership, approved data, validation, human review and correction pathways.
Risk ownership and assurance
Every principal risk should have an executive owner, a defined control standard, evidence of independent challenge and a threshold for Board escalation. The director will test whether quality, regulatory, information-security and business-continuity assurance examine the same critical path or leave gaps between functions. Closure will mean demonstrated control performance over time; an accepted action plan, revised procedure or target date is not itself remediation.
Product and quality consequence
The Board should receive serious deviations, complaints, field events, recalls or corrective actions in consequence terms. Recurrence and near misses can be more informative than a lagging count. The director will ask whether operating and commercial incentives influence escalation, investigation or closure.
CSR and access
Programmes should define the unmet need, beneficiary, delivery model, accountable technical authority, safeguard, outcome and exit. Health access is not proven by units distributed or people reached. The committee will examine continuity, appropriate use, follow-up and whether activity produced a defensible benefit.
Implementing partners need competence, financial integrity, safeguarding, local legitimacy and data protection. Programme selection must remain distinct from commercial influence, referral or market access. Beneficiaries should have a grievance and remedy route appropriate to the potential harm.
First-year contribution
The appointee will lead one integrated scenario joining a high-consequence operating risk with customer/patient response and community impact. Separately, the director will require one material CSR programme to be assessed against an independent outcome baseline rather than activity volume.
Candidate profile
Suitable candidates include healthcare or life-sciences CEOs, quality/regulatory leaders with enterprise breadth, CROs, public-health executives, clinicians with board experience and governance-grade CSR/ESG leaders. Applicants must understand both consequence and oversight boundaries. Independence, DIN and databank compliance are required, together with availability during a significant quality, supply or data event.